{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:53:33Z","timestamp":1770414813184,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81470493"],"award-info":[{"award-number":["81470493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Natural Science Basic Research Plan in Shaanxi Province","award":["2013JM4022"],"award-info":[{"award-number":["2013JM4022"]}]},{"name":"Shaanxi 100 Talents Program"},{"name":"Xi\u05f3an Medical University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ejphar.2014.08.037","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T04:29:15Z","timestamp":1410841755000},"page":"166-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Apolipoprotein B, the villain in the drama?"],"prefix":"10.1016","volume":"748","author":[{"given":"Qi","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cang-Bao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2014.08.037_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.ATV.0000255580.73689.8e","article-title":"Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study","volume":"27","author":"Benn","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2014.08.037_bib2","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2014.08.037_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jacl.2013.09.004","article-title":"JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia","volume":"8","author":"Brown","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ejphar.2014.08.037_bib4","doi-asserted-by":"crossref","first-page":"e73761","DOI":"10.1371\/journal.pone.0073761","article-title":"Altered endothelin receptor expression and affinity in spontaneously hypertensive rat cerebral and coronary arteries","volume":"8","author":"Cao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2014.08.037_bib5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s10439-007-9426-3","article-title":"Effects of disturbed flow on endothelial cells","volume":"36","author":"Chien","year":"2008","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.ejphar.2014.08.037_bib6","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1161\/01.CIR.0000038419.53000.D6","article-title":"Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy","volume":"106","author":"Grundy","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2014.08.037_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1476-511X-12-107","article-title":"Argan oil prevents prothrombotic complications by lowering lipid levels and platelet aggregation, enhancing oxidative status in dyslipidemic patients from the area of Rabat (Morocco)","volume":"12","author":"Haimeur","year":"2013","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.ejphar.2014.08.037_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/ATVBAHA.111.242800","article-title":"Regulatory T-cell response to apolipoprotein B100-derived peptides reduces the development and progression of atherosclerosis in mice","volume":"32","author":"Herbin","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2014.08.037_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1388-1981(00)00123-2","article-title":"Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL","volume":"1488","author":"Hevonoja","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2014.08.037_bib10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bbalip.2011.12.001","article-title":"Minimally modified LDL upregulates endothelin type B receptors in rat coronary artery via ERK1\/2 MAPK and NF-kappaB pathways","volume":"1821","author":"Jie","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2014.08.037_bib11","doi-asserted-by":"crossref","first-page":"471","DOI":"10.33549\/physiolres.930533","article-title":"Hyperlipoproteinemia impairs endothelium-dependent vasodilation","volume":"53","author":"Kraml","year":"2004","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ejphar.2014.08.037_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2014.08.037_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.atherosclerosis.2006.02.027","article-title":"Vasodilation in resistance arteries is related to the apolipoprotein B\/A1 ratio in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study","volume":"190","author":"Lind","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2014.08.037_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-90-481-8622-8_7","article-title":"High density lipoprotein structure-function and role in reverse cholesterol transport","volume":"51","author":"Lund-Katz","year":"2010","journal-title":"Subcell. Biochem."},{"key":"10.1016\/j.ejphar.2014.08.037_bib15","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2337\/db08-1794","article-title":"Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites","volume":"58","author":"Martin","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2014.08.037_bib16","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1016\/j.jacc.2013.07.083","article-title":"Lipid control in the modern era: an orphan\u05f3s tale of rags to riches","volume":"62","author":"Milani","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.08.037_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.jhh.1002317","article-title":"Increased ET(A) and ET(B) receptor contraction in the left internal mammary artery from patients with hypertension","volume":"22","author":"Nilsson","year":"2008","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejphar.2014.08.037_bib18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/MOL.0b013e328356ec7c","article-title":"Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential","volume":"23","author":"Nilsson","year":"2012","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejphar.2014.08.037_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/erv.13.4","article-title":"Vaccines against atherosclerosis","volume":"12","author":"Nilsson","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ejphar.2014.08.037_bib20","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/CIRCULATIONAHA.104.532499","article-title":"Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men","volume":"112","author":"Pischon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2014.08.037_bib21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2014.08.037_bib22","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/eurheartj\/ehn336","article-title":"High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction","volume":"29","author":"Sjogren","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2014.08.037_bib23","doi-asserted-by":"crossref","first-page":"20963","DOI":"10.1074\/jbc.272.34.20963","article-title":"Low density lipoprotein oxidation and its pathobiological significance","volume":"272","author":"Steinberg","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2014.08.037_bib24","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1161\/01.STR.0000028183.04277.32","article-title":"Cerebral ischemia upregulates vascular endothelin ET(B) receptors in rat","volume":"33","author":"Stenman","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.ejphar.2014.08.037_bib25","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2014.08.037_bib26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","article-title":"The apoB\/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence","volume":"259","author":"Walldius","year":"2006","journal-title":"J. Intern Med."},{"key":"10.1016\/j.ejphar.2014.08.037_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2010.04.013","article-title":"Cardiovascular risk factors regulate the expression of vascular endothelin receptors","volume":"127","author":"Xu","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2014.08.037_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.vph.2013.11.004","article-title":"Low density lipoprotein induces upregulation of vasoconstrictive endothelin type B receptor expression","volume":"60","author":"Xu","year":"2014","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.ejphar.2014.08.037_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cca.2013.06.006","article-title":"Foam cells in atherosclerosis","volume":"424","author":"Yu","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejphar.2014.08.037_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2014.01.008","article-title":"Apolipoprotein B of low-density lipoprotein impairs nitric oxide-mediated endothelium-dependent relaxation in rat mesenteric arteries","volume":"725","author":"Zhang","year":"2014","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914006426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299914006426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T15:20:32Z","timestamp":1689520832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299914006426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":30,"alternative-id":["S0014299914006426"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.08.037","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apolipoprotein B, the villain in the drama?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2014.08.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}